OBJECTIVE: Previous studies have demonstrated that leptin inhibits glucose-stimulated insulin secretion from isolated islets, although a lack of leptin effect on insulin secretion has also been reported. The effect of long term in vivo leptin treatment of insulin secretion has, however, not been established. Therefore, in the present study, we have evaluated the effect of long term in vivo treatment of leptin on glucose-induced insulin secretion in obaob mice. METHODS: After 7 days' treatment of leptin (100 mg daily s.c.), insulin release was measured in isolated islets by batch incubation followed by radioimmunoassay. Glucose utilization and oxidation were measured by measuring the formation of 3 H 2 O and 14 CO 2 from [5-3 H] and [U-14 C] glucose, respectively. Glucose-6-phosphatase activity was measured by measuring the conversion of 14 C-glucose-6-P to 14 C-glucose. In addition, immunohistochemistry of pancreatic specimens was undertaken for study of expression of insulin, GLUT-2 and hormone-sensitive lipase (HSL). RESULTS: Leptin treatment signi®cantly improved insulin secretion both at 5.5 mM (by 15%; P`0.05) and 16.7 mM (by 85%; P`0.001) glucose, compared to vehicle-treated controls. Furthermore, whereas leptin treatment did not affect islet insulin or DNA contents, a signi®cant decrease in islet triglyceride content and glucose-6-phosphatase activity was observed. Moreover, the immunocytochemical data revealed an increased immunostaining for insulin, GLUT-2 and hormone-sensitive lipase (HSL) in islets from leptin-treated obaob mice.
Introduction
Leptin, the protein encoded by the obese (ob) gene, is synthesized and released in adipose tissue. 1, 2 Leptin controls body weight by decreasing food intake and increasing energy expenditure. 1, 2 The de®ciency of leptin in the obese obaob mouse is re¯ected by increased body weight, hyperglycemia and hyperinsulinemia. 3, 4 Consequently, the treatment of obaob mice with leptin results in a reduction of food intake and body weight and also normalizes blood glucose and plasma insulin levels. 2, 5, 6 The normalization of blood glucose and plasma insulin levels has been considered to be mainly due to decreased glucose production and improved insulin sensitivity in these animals. 7 Since leptin treatment improves hyperglycemia by an effect which is not completely dependent on decreased body weight and improved metabolic control, 8 it is possible that leptin administration in vivo, in parallel to its known effects on satiety and energy expenditure, can also stimulate insulin secretion from the bcell. The effects of long-term leptin treatment on insulin secretion have not been established. Most in vitro studies have, however, shown that leptin inhibits glucose-stimulated insulin secretion, 9 ,10 although a lack of effect has also been reported. 11, 12 The mechanism underlying this inhibitory effect of leptin has been thought to be the result of signalling through the JAKaSTAT pathway in b-cells. 13, 14 In the present study, we have investigated the effect of leptin on insulin release after the prolonged in vivo treatment of obaob mice. We report that 7 days of treatment with leptin signi®cantly improves glucose-induced insulin secretion in conjuction with reductions in islet triglyceride content and glucose-6-phosphatase activity and increases the expression of hormone-sensitive lipase (HSL) and GLUT-2, which might be partially responsible for the improved glycemia in leptintreated obaob mice. C]glucose-6-P (disolium salt), 57.7 mCiammol, was obtained from Dupont NEN, Boston MA. Glucose-6-P, bglycerol-P, HEPES and triglyceride kits (GPO-Trinder) were purchased from Sigma Chemicals (St Louis, MO). Amberlite MB-3 monobed resin was from BDH (Poole, UK). Biosynthetic mature human leptin was a gift from Eli Lilly & Co (Indianapolis IN) .
Material and methods
Obese obaob mice, bred in our laboratory, aged 10 ± 12 months and weighing 50 ± 61 g were used for the study. One group of mice was injected daily for 1 week intraperitoneally with 100 mg leptin in 0.1 ml phosphate-buffered saline (PBS) and another group with only 0.1 ml PBS (vehicle). All animals were fed ad libitum with free access to water and were kept in a room in which a 12 h light ± dark cycle (6 am to 6 pm) was enforced. Leptin was injected in obaob mice at 5 pm each day and the animals were killed at 8 am on the day after the last leptin injection for the isolation of islets. Blood was collected at the time of decapitation to measure glucose and insulin.
Islet isolation
The pancreata of the animals were digested for 8 ± 10 min with continuous shaking (150 strokeamin) at 37 C in 4 ml Hanks' solution with 8 mg of collagenase. The sediment was washed several times with cold Hanks' solution and the islets from the sediment were collected using a glass pipette under a sterieomicroscope.
Insulin release
All islets were preincubated in Krebs-bicarbonate buffer (pH 7.4; KRB) containing 3.3 mM glucose for 30 min. Batches of three islets were then incubated in triplicate for 1 h at 37 C in 300 ml KRB, containing 2 mgaml bovine albumin and 5.5 or 16.7 mM glucose. After the incubation, an aliquot of the medium was stored at À70 C for measurement of insulin, and the islets were washed with glucose-free KRB buffer and insulin from the islets was extracted with acid ± alcohol. 15 Insulin was measured by radioimmunoassay with the addition of charcoal to separate free and bound antibody. 16 Glucose utilization and oxidation For the measurement of glucose utilization and oxidation, groups of 25 islets were placed in incubation vials with either 5.5 or 16.7 mM glucose (in duplicate), 0.5% BSA (fraction V) and 1 mCi of [5- 3 H]glucose and 1 mCi of [U- 14 C]glucose in 100 ml of KRB. Each vial with its contents was placed in a scintillation bottle, sealed and gassed with 95% O 2 : 5% CO 2 for 3 min. After 90 min incubation at 37 C, 100 ml of 10% (vav) perchloric acid was injected into the vial, and 250 ml volumes of Hyamine (Packard Instrument Co, Meriden, CT) and 250 ml water were injected into the scintillation bottle to absorb 14 
Islet G6Pase activity
Batches of 25 islets (in duplicate) were placed in tubes containing 50 mM HEPES (pH 7.4), 20 mM b-glycerol-P and 0.5 mCi of [1-14 C]glucose-6-P (4 mM), and the tubes were immersed in ethanol ± dry ice for 10 s to permeabilize the islets. Other batches of 25 islets (in duplicate) were placed in tubes containing only HEPES buffer and were sonicated for 5 ± 10 s to disrupt the membrane. Then, 4 mM [1-
14
C]glucose-6-P was added. Incubation volume was 100 ml. The tubes with their content were incubated for 20 min at 37 C and the reaction was stopped by placing the tubes in ice ± water, followed by the additions of 0.3 ml 0.3 M ZnSO 4 and, after mixing, 0.3 ml saturated Ba(OH) 2 .
After stopping the incubations, 2 mg glucose were added to each tube, followed by vortexing and centrifugation for 2 min in an Eppendorf centrifuge (10 000 g). The supernatant was passed through MB-3 resin, and the ef¯uent was evaporated to dryness and dissolved in 1 ml water. Five-hundred microlitre of this solution were counted for radioactivity and the remainder was used for the measurement of glucose concentration, using a glucose oxidase method (Glucose Analyzer, Model 23A, Yellow Springs Instruments Co., Yellow Springs, OH). 7 Insulin release in obaob mouse islets A Khan et al Measurements of triglyceride and DNA Batches of 250 ± 300 islets were sonicated in 50 ml buffer containing 2 mM NaCl, 20 mM EDTA and 50 mM sodium phosphate (pH 7.4). A 10 ml volume of homogenate was mixed with 10 ml of tert-butyl alcohol and 5 ml of Triton X100amethyl alcohol mixture (1 : 1 by volume) for the extraction of lipids. Triglycerides (TG) were measured with the Sigma triglyceride (GPO-Trinder) kit. 18 Islet DNA content was measured by the method of Hinegardner.
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Tissue processing for immunocytochemistry Pancreatic specimens were ®xed by immersion overnight in Stefanini's ®xative (2% formaldehyde and 0.2% picric acid in phosphate buffer, pH 7.2), rinsed repeatedly in Tyrode solution enriched with sucrose (10% wav) and frozen on dry ice. Sections (10 mm thickness) were cut in a cryostat, collected on chrome alum-coated slides and then processed for immunocytochemistry. Guinea pig anti-human proinsulin (code 9003, Euro-Diagnostica, Malmo È, Sweden, dilution 1 : 1280) and af®nity-puri®ed chicken anti-rat HSL (dilution 1 : 320) antibodies were used; these have been previously characterized at the immunocytochemical level. 20 GLUT-2 antiserum was purchased from Sigma, St Louis, MO and was used at a dilution of 1 : 640. The site of the antigen ± antibody reaction was visualised by¯uorescein isothiocyanateconjugated antibody to IgG raised in pig (Dakopatts, Copenhagen, Denmark).
Statistical analysis
Results are presented as means AE s.e.m. Student's t-test for unpaired data was used for the statistical evaluation of the data.
Results
Treatment of obaob mice with leptin for 7 days decreased body weight by about 10% compared to vehicle-treated obaob mice (control) ( Table 1 ). This was accompanied by reduced blood glucose and plasma insulin concentrations. Analysis of the isolated islets revealed that their DNA and insulin contents were unaffected by leptin treatment, while islet triglyceride levels were signi®cantly lower in leptintreated mice than in controls (P`0.05, Table 2 ). Furthermore, insulin release was signi®cantly higher in islets from leptin-treated mice than controls at 5.5 mM glucose ( Figure   1 ). This basal insulin release was increased by raising the glucose concentration to 16.7 mM by about 6.5-fold in leptin-treated mice and about 4 fold in control mice. Hence, leptin treatment of obaob mice improved GSIS.
Islets from mice treated with leptin for 7 days utilized and oxidized as much glucose as islets from control mice at 5.5 mM glucose (Figure 2 ). At 16.7 mM glucose, glucose utilization and oxidation increased signi®cantly, both in leptin-treated and control mice compared to 5.5 mM glucose. However, both glucose utilization and oxidation were signi®cantly lower in leptin-treated mice compared to controls (P`0.05).
G6Pase activity at 4 mM glucose-6-P was signi®cantly higher in sonicated islets than in permeabilized islets from Insulin release in obaob mouse islets A Khan et al leptin-treated and control mice. The enzyme activity was signi®cantly lower in islets from leptin-treated mice, compared to controls, irrespective of whether permeabilized or sonicated islets were used ( Figure 3 ). Immunocytochemistry showed that many of the islets were conspicuously large in control obaob mice (Figure 4a) . The vast majority of islet cells displayed an insulin immunoreactivity of weak to moderate intensity. GLUT-2 immunoreactivity was barely detectable in the majority of islet cells ( Figure 4c) ; only scattered cells or clusters of cells were immunoreactive and the GLUT-2 immunoreactivity was concentrated at the cell membrane (Figure 4c ). HSL immunoreactivity was notably weak, and in some islets barely detectable in control obaob mice (Figure 4e ). In leptintreated obaob mice, the islets were generally smaller than those of control obaob mice, although occasional large islets were also seen. In comparison with control obaob mice, insulin immunoreactivity was intense in most of the immunoreactive cells in leptin-treated animals (Figure 4b) . Furthermore, intense GLUT-2 immunoreactivity surrounded the vast majority of islet cells, particularly those located more centrally in the islet (Figure 4d ). Finally, HSL immunoreactivity was markedly stronger in the islets after leptin treatment (Figure 4f ).
Discussion
Obese obaob mice provide an animal model of non-insulin dependent diabetes mellitus, exhibiting hyperglycemia, hyperinsulinemia and obesity. 3, 4 The ob syndrome is caused by a mutation in the ob gene leading to an absence of circulating leptin. 1 Leptin controls body weight, via both hypothalamic receptors that regulate food intake and energy metabolism, and peripheral receptors. The injection of leptin to obaob mice decreases adiposity, hyperglycemia and hyperinsulinemia. 1, 2, 8, 21 Since leptin receptors are present in the pancreatic islets of rodents, 23 it has been speculated that leptin may directly regulate insulin secretion from the b-cell. In accordance with this, leptin treatment in vitro has been shown to inhibit GSIS in islets from obaob and lean mice, 9, 10 normal rats 24, 25 and humans. 26, 27 In other studies, leptin was without any effect on GSIS.
12,13 These differences are most probably due to different experimental conditions, the dose or source of leptin, the duration of the leptin treatment and the lack of bioactivity of some preparations of leptin that have been used. The results are representative ®gures after evalution of three to six animals in each group. The islets were approximately 200 ± 300 ml in diameter as compared to 80 ± 120 ml in normal mice. Note the markedly higher intensity of each of the immunoreactants after leptin treatment (Â200).
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We show in the present study that 7 days of treatment with leptin to obaob mice signi®cantly decreased body weight, blood glucose and plasma insulin concentrations, which is in agreement with the earlier reports. 2, 5 However, the insulin content in islets from leptin-treated mice was not changed. Furthermore, islet size was reduced by leptin, indicating a rapid adjustment of the islet mass to the ambient requirement. The novel ®nding in this study is that the long-term treatment of obaob mice with leptin signi®cantly increased GSIS. This is important, since, based on the inhibitory effects of leptin on insulin secretion in vitro, it has been proposed that the failure of leptin to inhibit insulin secretion from the b-cells of obaob mice may explain in part the development of hyperinsulinemia, insulin resistance and the progression to diabetes. 10, 26 In agreement with the present data, it has been suggested that the long-term normalization of glucose tolerance in leptin gene treated obaob mice was not solely related to increased insulin sensitivity, but also due to improved insulin secretion. 7 We also show that leptin treatment decreased islet G6Pase activity. This decrease in enzyme activity may play a role in the improvement in GSIS due to leptin. G6Pase activity is increased, not only in obaob mice, but also in other animal models of diabetes such as Goto Kakisaki (GK) rats and rats neonatally treated with streptozotocin. 28 ± 30 Furthermore, G6Pase activity can be induced either by the diabetogenic hormone cortisone 16, 31 or by overexpression of the glucocorticoid receptors in the b-cells. 32 Since both of these manipulations decrease insulin release, a role for the regulation of insulin release by this enzyme has been proposed. Direct evidence for such a role was provided by previous experiments with INS-cells in which the overexpression of G6Pase by adenovirus transfection decreased insulin release. 33 However, the exact mechanisms by which G6Pase regulates GSIS have yet to be established. Increased G6Pase activity would increase the rate of islet glucose cycling leading to the consumption of one molecule of ATP for every glucose molecule entering the cycle. Adequate ATP production, and thereby the maintanance of a normal ATPaADP ratio, is necessary to maintain normal cellular functions, including the regulation of ATP-sensitive K -channels. 34 The closure of K -channels leads to a depolarisation of the b-cell plasma membrane, resulting in the opening of voltage-dependent Ca 2 -channels, an increase in cytoplasmic free Ca 2 -concentration, and insulin release. 35 A potentially important additional mechanism behind improved GSIS in leptin-treated obaob mice is the decrease in islet TG content which results in a reduced availability of free fatty acids (FFA). This hypothesis is supported by a series of studies of Unger and his associates demonstrating that TG levels in islets are of signi®cant importance for the regulation of GSIS. Thus, it has been shown that, in Zucker fatty rats, increased plasma FFA levels correlate with increased levels of TG in the islets, and are accompanied by an impaired GSIS and decreased GLUT-2 expression. 36, 37 In vivo, prolonged elevation of plasma FFA impairs insulin secretion. 38 Also, in vitro exposure of islets to FFA impairs GSIS and increases TG levels. 39 Furthermore, the reduction of islet TG levels resulting from the infusion of normal rats with a recombinant adenovirus encoding the leptin gene leads to the overexpression and 10-fold increase in plasma leptin levels or culturing normal rat islets with leptin for 3 days completely abolished GSIS, 40 whereas, treatment with fatty acids restored GSIS. 38 ± 41 These data indicate a window of TG and FFA for optimal GSIS and suggests that this is regulated by leptin. The mechanism of the reduction in cellular TG content by leptin has previously been suggested to be due to increased lipid b-oxidation due to the combined action of leptin in restricting the availability of malonyl-CoA, and by its activation of UCP2. 42 The results of the present study suggest that leptin may decrease islet TG content also by increasing the activity of islet HSL which was recently shown to be present in islets. 20 However, it remains to be demonstrated that the increase in HSL immunoreactivity indeed corresponds to an increased HSL activity, leading to enhanced lypolysis in the b-cells.
In conclusion, we have shown that leptin treatment of obaob mice improves GSIS. This improved insulin secretion is accompanied by decreased G6Pase activity, increased islet HSL expression and decreased islet triglyceride content. We suggest that these alterations contribute to normalization of glucose homeostasis after long-term treatment of leptin.
